Loading...
Loading...
In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on
MedivationMDVN with an Overweight rating and $130.00 price target.
In the report, Barclays Capital noted, “Medivation's Xtandi is now set to have broader reach in prostate cancer with a pre-chemo label and a focus on the much larger urologist prescriber base. As a result, we're ~10% ahead of consensus on total revenues in 2015. In addition, phase 2 data in 1H15 in two trials (STRIVE, TERRAIN) should further differentiate Xtandi from JNJ's Zytiga and could drive off-label use earlier in the prostate cancer paradigm. With beatable expectations for Xtandi in the US/EU/JPN and expansion ahead in prostate/breast cancer, we think that Medivation's momentum last year will persist in 2015. We're initiating coverage with an Overweight rating and $130 target.”
Medivation closed on Monday at $100.02.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in